NCT03653338View on ClinicalTrials.gov

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 2, 2018

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions
Sickle Cell AnemiaBeta-thalassemia MajorDiamond-blackfan Anemia
Interventions
BIOLOGICAL

CD3/CD19 depleted leukocytes

Negative selection for CD3+/CD19+ cells will be performed on the CliniMACS® depletion device.

BIOLOGICAL

CD45RA depleted leukocytes

Negative selection for CD45RA will be performed on the CliniMACS® depletion device.

DRUG

Hydroxyurea

Sickle Cell Disease Conditioning

DRUG

Rituximab

Sickle Cell Disease Conditioning

DRUG

Alemtuzumab

Sickle Cell Disease Conditioning

DRUG

Fludarabine

Sickle Cell Disease Conditioning

DRUG

Thiotepa

Sickle Cell Disease Conditioning

Trial Locations (1)

15224

RECRUITING

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

All Listed Sponsors
lead

Paul Szabolcs

OTHER